Re: Thioridazine: re-evaluating the risk/benefit equation.
Timell
Anna M
AM
Taconic Developmental Disabilities, Services Office, 26 Center Circle, Wassaic, New York 12592, USA.
D014150:Antipsychotic Agents / Q000009:adverse effects* / Q000627:therapeutic use; D003625:Data Collection; D003645:Death, Sudden / Q000209:etiology / Q000517:prevention & control; D004562:Electrocardiography; D005260:Female; D006801:Humans; D008133:Long QT Syndrome / Q000139:chemically induced* / Q000503:physiopathology / Q000517:prevention & control; D008297:Male; D001523:Mental Disorders / Q000188:drug therapy; D008875:Middle Aged; D018570:Risk Assessment; D018967:Risperidone / Q000009:adverse effects / Q000627:therapeutic use; D013881:Thioridazine / Q000009:adverse effects* / Q000627:therapeutic use
D014150:Antipsychotic Agents; D018967:Risperidone; D013881:Thioridazine